Clinical Trials in Cleveland

Showing 7901-7920 of 15,050 trials

Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone

NCT03762798

This is an open-label, single center study of The Bridge in patients with sustained remission of opiate dependence on established, low-dose MAT with buprenorphine. A fixed number of patients will be admitted to the study.

Substance Use DisordersSubstance AbuseSubstance Use+1 more

The Cleveland ClinicStarted Nov 2018

Cleveland, Ohio, United States

COMPLETEDPhase 2< 1 mile

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

NCT02844439

This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.

GlioblastomaRecurrent GlioblastomaBrain Tumor

Kadmon Corporation, LLC40 participantsStarted Jun 2016

Tucson, Arizona, United States • Duarte, California, United States • San Francisco, California, United States +8 more locations

TERMINATEDPhase 3< 1 mile

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

NCT02952586

This is a phase 3 randomized, placebo controlled study to evaluate the safety and anti-tumor activity of Avelumab in combination with standard of care chemoradiation (SoC CRT) versus SoC CRT alone in front-line treatment of patients with locally advanced head and neck cancer.

Squamous Cell Carcinoma of the Head and Neck

Pfizer697 participantsStarted Nov 2016

Fayetteville, Arkansas, United States • Rogers, Arkansas, United States • Springdale, Arkansas, United States +313 more locations

Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Find Trials by Condition in Cleveland

An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

OptiMesh® for Lumbar Interbody Fusion Trial (OLIF)

Dose Range Study of CD5789 in Acne Vulgaris

A Cohort Study of Operationally Tolerant Allograft Recipients

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Stress Management for Cancer Patients: How Well Does it Work? (C2H-D)

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)